Sandra Verploegen

2.4k citations

27 papers · 1.6k indexed · h-index 16

Radiology, Nuclear Medicine and Imaging top 2%
Oncology top 5%
Molecular Biology
Immunology top 5%
Hematology top 2%

Co-authors: Paul W.H.I. Parren Wim K. Bleeker Marije B. Overdijk Esther C.W. Breij Janine Schuurman Jeroen J. Lammerts van Bueren Marjolein van Egmond Richard W.J. Groen
Topics: Monoclonal and Polyclonal Antibodies Research (17 papers)Cell Adhesion Molecules Research (7 papers)HER2/EGFR in Cancer Research (6 papers)
Cited by: Hematology Radiology, Nuclear Medicine and Imaging Oncology
Journals: Proceedings of the National Academy of Sciences Journal of Clinical Oncology Blood
Partner nations: Netherlands United States Denmark

In The Last Decade

Sandra Verploegen

27 papers receiving 1.6k citations

Peers

Countries citing papers authored by Sandra Verploegen

Since Specialization

Citations

This map shows the geographic impact of Sandra Verploegen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra Verploegen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra Verploegen more than expected).

Fields of papers citing papers by Sandra Verploegen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra Verploegen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra Verploegen. The network helps show where Sandra Verploegen may publish in the future.

Co-authorship network of co-authors of Sandra Verploegen

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra Verploegen. A scholar is included among the top collaborators of Sandra Verploegen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra Verploegen. Sandra Verploegen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Logic-gated antibody pairs that selectively act on cells co-expressing two antigens 2022 ·Nature Biotechnology ·Simone C. Oostindie,(unknown),Gijs G. Zom,Michael J. Wester,(unknown),(unknown),Els van der Meijden,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Sandra Verploegen,Péter Boross,Frank J. Beurskens,Diane S. Lidke,Janine Schuurman,Rob N. de Jong	31
2	Epidermal Growth Factor Receptor as Target for Perioperative Elimination of Circulating Colorectal Cancer Cells 2022 ·Journal of Oncology ·(unknown),Rens Braster,Marije B. Overdijk,(unknown),Sandra Verploegen,(unknown),Berend J. van der Wilk,Paul W.H.I. Parren,Hans van Vliet,Marijn Bögels,Marjolein van Egmond	8
3	DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing 2020 ·EBioMedicine ·Patrick Engelberts,Ida H. Hiemstra,(unknown),Danita H. Schuurhuis,Joyce Meesters,Irati Beltrán Hernández,Simone C. Oostindie,Joost Neijssen,Edward N. van den Brink,G. Jean Horbach,Sandra Verploegen,Aran F. Labrijn,Theodora W. Salcedo,Janine Schuurman,Paul W.H.I. Parren,Esther C.W. Breij	102
4	Abstract 221: Tisotumab vedotin induces anti-tumor activity through MMAE-mediated, Fc-mediated, and Fab-mediated effector functions in vitro 2019 ·Cancer Research ·Stephen C. Alley,Jeffrey Harris,Anthony Cao,(unknown),Jyoti Velayudhan,David Satijn,Sandra Verploegen,(unknown),Esther C.W. Breij	17
5	Abstract 221: Tisotumab vedotin induces anti-tumor activity through MMAE-mediated, Fc-mediated, and Fab-mediated effector functionsin vitro 2019 ·Stephen C. Alley,Jeffrey R. Harris,Anthony Cao,(unknown),Jyoti Velayudhan,David Satijn,Sandra Verploegen,(unknown),Esther C.W. Breij	1
6	PS1301 POTENT ANTI‐TUMOR ACTIVITY OF DUOBODY^®‐CD3XCD20 IN PRECLINICAL MODELS IN VITRO AND IN VIVO 2019 ·HemaSphere ·Ida H. Hiemstra,Patrick Engelberts,(unknown),Danita H. Schuurhuis,Theodora W. Salcedo,Sandra Verploegen,M. van der Zee,P.A. Usher,(unknown),(unknown),Paul W.H.I. Parren,Aran F. Labrijn,Janine Schuurman,Esther C.W. Breij	1
7	CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory 2018 ·Molecular Cancer Therapeutics ·(unknown),Işıl Altıntaş,Marjolein Sluijter,Sandra Verploegen,Aran F. Labrijn,Danita H. Schuurhuis,Mischa Houtkamp,J. Sjef Verbeek,Janine Schuurman,Thorbald van Hall	61
8	Efficient Generation of Bispecific Murine Antibodies for Pre-Clinical Investigations in Syngeneic Rodent Models 2017 ·Scientific Reports ·Aran F. Labrijn,Joyce Meesters,Matthew W. Bunce,Anthony A. Armstrong,Sandeep Somani,(unknown),Mark L. Chiu,Işıl Altıntaş,Sandra Verploegen,Janine Schuurman,Paul W.H.I. Parren	31
9	A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface 2016 ·PLoS Biology ·Rob N. de Jong,Frank J. Beurskens,Sandra Verploegen,Kristin Strumane,Muriel D. van Kampen,Marleen Voorhorst,(unknown),Patrick Engelberts,Simone C. Oostindie,Guanbo Wang,Albert J. R. Heck,Janine Schuurman,Paul W.H.I. Parren	153
10	Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma 2015 ·mAbs ·Marije B. Overdijk,Sandra Verploegen,Marijn Bögels,Marjolein van Egmond,Jeroen J. Lammerts van Bueren,Tuna Mutis,Richard W.J. Groen,Esther C.W. Breij,Anton C. Martens,Wim K. Bleeker,Paul W.H.I. Parren	370
11	Preclinical efficacy studies using HuMax-Axl-ADC, a novel antibody-drug conjugate targeting Axl-expressing solid cancers. 2015 ·Journal of Clinical Oncology ·Esther C.W. Breij,Sandra Verploegen,Andreas Lingnau,Edward N. van den Brink,Maarten L. Janmaat,Mischa Houtkamp,Wim K. Bleeker,David Satijn,Paul W.H.I. Parren	6
12	An Antibody–Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors 2013 ·Cancer Research ·Esther C.W. Breij,Bart E.C.G. de Goeij,Sandra Verploegen,Danita H. Schuurhuis,Ali Amirkhosravi,John Francis,(unknown),Mischa Houtkamp,Wim K. Bleeker,David Satijn,Paul W.H.I. Parren	166
13	Crosstalk between Human IgG Isotypes and Murine Effector Cells 2012 ·The Journal of Immunology ·Marije B. Overdijk,Sandra Verploegen,Antonio Ortiz Buijsse,Tom Vink,Jeanette H.W. Leusen,Wim K. Bleeker,Paul W.H.I. Parren	157
14	Phagocytosis Is A Mechanism of Action for Daratumumab 2012 ·Blood ·Marije B. Overdijk,Sandra Verploegen,(unknown),Marjolein van Egmond,Richard W.J. Groen,Anton C. Martens,Jeroen Lammerts van Bueren,Wim K. Bleeker,Paul W.H.I. Parren	12
15	Characterization of the role of CaMKI-like kinase (CKLiK) in human granulocyte function 2005 ·Blood ·Sandra Verploegen,Laurien H. Ulfman,Hanneke W. M. van Deutekom,(unknown),Henk Honing,Jan‐Willem J. Lammers,Leo Koenderman,Paul J. Coffer	39
16	Role of Ca²⁺/calmodulin regulated signaling pathways in chemoattractant induced neutrophil effector functions 2002 ·European Journal of Biochemistry ·Sandra Verploegen,(unknown),Hanneke W. M. van Deutekom,Jan‐Willem J. Lammers,Leo Koenderman,Paul J. Coffer	26
17	Identification of cytokine-regulated genes in human leukocytes in vivo 2000 ·Journal of Allergy and Clinical Immunology ·(unknown),Sandra Verploegen,Jan A. M. Raaijmakers,Jan‐Willem J. Lammers,Leo Koenderman,Paul J. Coffer	9
18	Identification and characterization of CKLiK, a novel granulocyte Ca++/calmodulin-dependent kinase 2000 ·Blood ·Sandra Verploegen,Jan‐Willem J. Lammers,Leo Koenderman,Paul J. Coffer	32
19	Identification and characterization of CKLiK, a novel granulocyte Ca++/calmodulin-dependent kinase 2000 ·Blood ·Sandra Verploegen,Jan‐Willem J. Lammers,Leo Koenderman,Paul J. Coffer	2
20	A human leptin mutant induces weight gain in normal mice 1997 ·FEBS Letters ·Sandra Verploegen,Geert Plaetinck,René Devos,José Van der Heyden,Yves Guisez	63

About Sandra Verploegen

Sandra Verploegen is a scholar working on Immunology and Allergy, Radiology, Nuclear Medicine and Imaging and Oncology, having authored 27 papers that have together received 1.6k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (17 papers), Cell Adhesion Molecules Research (7 papers) and HER2/EGFR in Cancer Research (6 papers). The work is most often cited by research in Hematology (368 citations), Radiology, Nuclear Medicine and Imaging (729 citations) and Oncology (709 citations). Sandra Verploegen has collaborated with scholars based in Netherlands, United States and Denmark. Frequent co-authors include Paul W.H.I. Parren, Wim K. Bleeker, Marije B. Overdijk, Esther C.W. Breij, Janine Schuurman, Jeroen J. Lammerts van Bueren, Marjolein van Egmond, Richard W.J. Groen, Anton C. Martens and Marijn Bögels. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact